Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Tolmar Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT05645536
- Locations
- 🇺🇸
Texas Oncology - Central South, Austin, Texas, United States
🇧🇷Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
🇺🇸Marin Cancer Care, Inc., Greenbrae, California, United States
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
- Conditions
- Breast NeoplasmsInvasive Breast CancerEstrogen-receptor-positive Breast CancerHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT05607004
- Locations
- 🇺🇸
Tranquility Research, Webster, Texas, United States
🇺🇸Bon Secours Cancer Institute, Midlothian, Virginia, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 8000
- Registration Number
- NCT05514054
- Locations
- 🇮🇹
Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia, Candiolo, Torino, Italy
🇮🇹Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana, Italy
🇮🇹Aou Ospedali Riuniti Umberto I, Ancona, Italy
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
- Conditions
- HER2-negative Breast CancerStage IIB Breast CancerStage III Breast CancerER-positive Breast Cancer
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-01-24
- Target Recruit Count
- 220
- Registration Number
- NCT05512364
- Locations
- 🇧🇪
Institut Jules Bordet, Anderlecht, Belgium
🇧🇪Pole Hospitalier Jolimont - Hopital Jolimont, Haine-Saint-Paul, Belgium
🇧🇪CHU Site Sainte-Elisabeth-UCL Namur, Namur, Belgium
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
- Conditions
- Locoregional RecurrenceHormone Receptor-positive Breast CancerHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Oana Danciu
- Target Recruit Count
- 200
- Registration Number
- NCT05467891
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Arizona, Phoenix, Arizona, United States
🇺🇸Orlando Health Cancer Institute, Orlando, Florida, United States
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
- Conditions
- Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05306340
- Locations
- 🇯🇵
Nagoya University Hospital, Aichi, Japan
🇿🇦Medical Oncology Centre of Rosebank, Johannesburg, South Africa
🇪🇸Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología, La Coruña, LA Coruna, Spain
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
- Conditions
- Node-negative Breast CancerBreast CarcinomaBreast CancerHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Irada Ibrahim-zada
- Target Recruit Count
- 70
- Registration Number
- NCT05150652
- Locations
- 🇺🇸
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Veru Inc.
- Registration Number
- NCT05079360
- Locations
- 🇺🇸
Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸California Research Institute (CRI), Los Angeles, California, United States
🇺🇸Banner Health/ Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
- Conditions
- ER+ Breast CancerHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 1100
- Registration Number
- NCT04985266
- Locations
- 🇬🇧
Barnet Hospital, London, Barnet, United Kingdom
🇬🇧Royal Sussex Hospital, Brighton, United Kingdom
🇬🇧Velindre Cancer Centre, Cardiff, United Kingdom
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
- Conditions
- Neoplasm MetastasisBreast Neoplasms
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 866
- Registration Number
- NCT04975308
- Locations
- 🇺🇸
USO - Texas Oncology - Allen, Allen, Texas, United States
🇦🇺Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia
🇺🇸Ironwood Cancer & Research Centers, Chandler, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.